Lethal prostate cancer: Finding it early and identifying effective treatments
Mohammad has keen interest and research expertise in the area of Prostate cancer (PCa). PCa is a leading cause of cancer related mortality in the United Kingdom with 11,000 deaths each year. There are a number of hurdles in the successful clinical management of the disease. On one side of the spectrum, Prostate-specific antigen (PSA) screening does reduce the risk of dying of PCa by 20%, however there are a number of cases of overdiagnosis and overtreatment inherent in PCa screening which is fairly non-specific. Therefore, to identify which patients must receive treatment and which patients should be monitored by “watchful waiting” is a clinical challenge. On the other side of the spectrum, why standard hormone therapy fails and how cancer becomes aggressive is poorly understood and leaves PCa patients with limited treatment options.
Dr. Asim’s strongly believes that a multi-dimension interdisciplinary research to attack PCa from different angles holds the key for the development of successful therapies with sustained clinical benefits. In terms of early detection, understanding underlying biology behind early disease could pave the way towards development of more specific diagnostic tools and will be vital in PCa patient survival, to avoid unnecessary overtreatment for those who do not need it and to decrease financial burden on health services. Moreover, understanding mechanisms that allow the disease to progress and become aggressive is vital in identifying novel therapeutic targets and thus important in designing novel therapies to treat PCa. Mohammad’s current research projects include:
1. Understanding the onset of PCa to develop precision diagnostic tools.
2. To understand the function of AR in the end-of-spectrum disease.
3. Identification and validation of novel potential drug targets in PCa.
4. Designing novel strategies to block PCa progression.
Dr Asim is pleased to consider applications from prospective doctoral students and self-funded postdocs.
BMS2036: Molecular Biology and Genetics: Introduction to Cancer
1. Lecturer in the Department of Clinical and Experimental Medicine, University of Surrey.
2. Visiting scientist, Cancer Research UK Cambridge Institute, University of Cambridge.
3. Surrey Cancer Research Institute.
Archives of Biochemistry and Biophysics, Cancer Research, Cellular Physiology and Biochemistry, Clinical Cancer Research, Cancer Letters, Molecular and Cellular Biochemistry, BMC Urology, The Journal of Biochemical and Molecular Toxicology, Life Sciences, Neuroscience, Hormones and Cancer, Endocrine-related Cancer, Pharmaceutical Biology, PLoS One, Diagnostic Pathology, Tumour Biology, Environmental Science and Pollution Research, Toxicology Mechanisms and Methods, Open Biology
Lead contributor in the discovery for which, a United States patent (#US20100010078 A1) has been obtained “Method of treating androgen dependent prostate cancer by administering an active pharmaceutical ingredient being Fisetin, 3,3',4',7- tertahydroxyflavone or a derivative thereof, in an oral, transdermal or topical dosage form.”
Member of the clinical trial management committee of the clinical trial entitled “A study into the pharmacodynamic biomarker effects of Olaparib (a PARP inhibitor) given prior to radical prostatectomy” protocol number CANCAP03, at the University of Cambridge Addenbrooke’s hospital, Cambridge. Study funded by AZ.
Mon-Fri, by appointment only.
Tel: 01483 68 4387
Ross-Adams H, Ball S, Lawrenson K, Halim S, Russell R, Wells C, Strand SH, Ørntoft TF, Larson M, Armasu S, Massie CE, Asim M, Mortensen MM, Borre M, Woodfine K, Warren AY, Lamb AD, Kay J, Whitaker H, Ramos-Montoya A, Murrell A, Sørensen KD, Fridley BL, Goode EL, Gayther SA, Masters J, Neal DE, Mills IG. (2016) ‘HNF1B variants associate with promoter methylation and regulate gene networks activated in prostate and ovarian cancer.’ Oncotarget. 2016 Oct 9.
Asim M, Massie CE, Neal DE. (2016) ‘Kinase joins the chaperone club: Androgen-regulated kinome reveals choline kinase alpha as a potential drug target in prostate cancer.’ Mol Cell Oncol. 2016 Feb 24;3(3):e1140262.
Asim M$, Massie CE, Orafidiya F, Pértega-Gomes N, Warren AY, Selth LA, Zecchini HI, Qureshi A, Baridi A, Menon S, Madhu B, Escriu C, Lyons S, Zecchini V, Shaw G, Hessenkemper W, Russell R, Mohammed H, Stefanos N, Lynch AG, Grigorenko E, D’Santos C, Taylor C, Lamb A, Sriranjan R, Yang J, Stark R, Dehm SM, Rennie PS, Baniahmad A, Carroll JS, Griffiths JR, Tavaré S, McEwan IJ, Mills IG, Tilley WD, & Neal DE. (2016) ‘Choline kinase alpha is an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target’ J Natl Cancer Inst. 11;108(5). ($Joint first and corresponding author)
Pertega-Gomes N, Felisbino S, Massie CE, Vizcaino JR, Coelho R, Sandi C, Sousa S, Jurmeister S, Ramos-Montoya A, Asim M, Tran M, Oliveira E, Lobo da Cunha A, Maximo V, Baltazar F, Neal DE, Fryer LG. (2015) ‘A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: A role for Monocarboxylate Transporters as metabolic targets for therapy.’ J Pathol. Aug;236(4):517-30.
Mahmood I, Ahmad I, Asim M, Lopes TT, Costa L (2014) ‘Silica-coated iron oxide nano-particles in vitro genotoxicity assessment and its interference with mercury co-exposure in European eel Anguilla anguilla L.’ Environmental Science and Pollution Research Mar;22(5):3687-96.
Zecchini V, Madhu B, Russell R, Pértega-Gomes N, Warren A, Gaude E, Borlido J, Stark R, Zecchini HI, Rao R, Scott H, Boren J, Massie C, Asim M, Brindle K, Griffiths J, Frezza C, Neal D, Mills IG. (2014) ‘Nuclear ARRB1 induces pseudohypoxia and cellular metabolism reprogramming in prostate cancer.’ EMBO Journal Jun 17;33(12):1365-82.
Eckey M, Kraft F, Kob R, Escher N, Asim M, Fischer H, Fritsche MK, Melle C, Baniahmad A. (2013) ‘The corepressor activity of Alien is controlled by CBP/p300.’ FEBS Journal Apr;280(8):1861-8.
Altay G, Asim M, Markowetz F, Neal DE. (2011) ‘Differential C3NET reveals disease networks of direct physical interactions.’ BMC Bioinformatics Jul 21;12:296.
Asim M, Hafeez BB, Siddiqui IA, Gerlach C, Patz M, Mukhtar H, Baniahmad A. (2011) ‘Ligand-dependent corepressor acts as a novel androgen receptor corepressor, inhibits prostate cancer growth, and is functionally inactivated by the Src protein kinase.’ Journal of Biological Chemistry Oct 28;286(43):37108-17.
Siddiqui IA, Asim M$, Hafeez BB, Adhami VM, Tarapore RS, Mukhtar H. (2011) ‘Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer.’ FASEB Journal Apr;25(4):1198-207 ($Joint first author)
Saleem M, Murtaza I, Tarapore RS, Suh Y, Adhami VM, Johnson JJ, Siddiqui IA, Khan N, Asim M, Hafeez BB, Shekhani MT, Li B, Mukhtar H. (2009) ‘Lupeol inhibits proliferation of human prostate cancer cells by targeting beta-catenin signaling.’ Carcinogenesis May;30(5):808-17.
Eisold M, Asim M, Eskelinen H, Linke T, Baniahmad A. (2009) ‘Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.’ J Mol Endocrinol. May;42(5):429-35.
Siddiqui IA, Adhami VM, Bharali DJ, Hafeez BB, Asim M, Khwaja SI, Ahmad N, Cui H, Mousa SA, Mukhtar H. (2009) ‘Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate.’ Cancer Research Mar 1;69(5):1712-6.
Hafeez BB, Adhami VM, Asim M, Siddiqui IA, Bhat KM, Zhong W, Saleem M, Din M, Setaluri V, Mukhtar H. (2009) ‘Targeted knockdown of Notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activator.’ Clin Cancer Research Jan 15;15(2):452-9.
Khan N, Asim M$, Afaq F, Abu Zaid M, Mukhtar H. (2008) ‘A novel dietary flavonoid fisetin inhibits androgen receptor signaling and tumor growth in athymic nude mice.’ Cancer Research Oct 15;68(20):8555-63. ($Joint first author)
Asim M$, Siddiqui IA, Hafeez BB, Baniahmad A, Mukhtar H. (2008) ‘Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells.’ Oncogene Jun 5;27(25):3596-604. ($Joint first author)
Hafeez BB, Asim M, Siddiqui IA, Adhami VM, Murtaza I, Mukhtar H. (2008) ‘Delphinidin, a dietary anthocyanidin in pigmented fruits and vegetables: a new weapon to blunt prostate cancer growth.’ Cell Cycle 2008 Nov 1;7(21):3320-6.
Hafeez BB, Siddiqui IA, Asim M, Malik A, Afaq F, Adhami VM, Saleem M, Din M, Mukhtar H. (2008) ‘A dietary anthocyanidin delphinidin induces apoptosis of human prostate cancer PC3 cells in vitro and in vivo: involvement of nuclear factor-kappaB signaling.’ Cancer Research 2008 Oct 15;68(20):8564-72.
Saleem M, Maddodi N, Abu Zaid M, Khan N, bin Hafeez B, Asim M, Suh Y, Yun JM, Setaluri V, Mukhtar H. (2008) ‘Lupeol inhibits growth of highly aggressive human metastatic melanoma cells in vitro and in vivo by inducing apoptosis.’ Clin Cancer Research Apr 1;14(7):2119-27.
Siddiqui IA, Shukla Y, Adhami VM, Sarfaraz S, Asim M, Hafeez BB, Mukhtar H. (2008) ‘Suppression of NFkappaB and its regulated gene products by oral administration of green tea polyphenols in an autochthonous mouse prostate cancer model.’ Pharm Res. Sep;25(9):2135-42.
Moehren U, Papaioannou M, Reeb CA, Grasselli A, Nanni S, Asim M, Roell D, Prade I, Farsetti A, Baniahmad A. (2008) ‘Wild-type but not mutant androgen receptor inhibits expression of the hTERT telomerase subunit: a novel role of AR mutation for prostate cancer development.’ FASEB Journal Apr;22(4):1258-67.
Siddiqui IA, Malik A, Adhami VM, Asim M, Hafeez BB, Sarfaraz S, Mukhtar H. (2008) ‘Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis.’ Oncogene Mar 27;27(14):2055-63.
Siddiqui IA, Saleem M, Adhami VM, Asim M, Mukhtar H. (2007) ‘Tea beverage in chemoprevention and chemotherapy of prostate cancer.’ Acta Pharmacol Sin. Sep;28(9):1392-408.
Gessner G, Schönherr K, Soom M, Hansel A, Asim M, Baniahmad A, Derst C, Hoshi T, Heinemann SH. (2005) ‘BKCa channels activating at resting potential without calcium in LNCaP prostate cancer cells.’ J Membr Biol. Dec;208(3):229-40.
Papaioannou M, Reeb C, Asim M, Dotzlaw H, Baniahmad A. (2005) ‘Co-activator and corepressor interplay on the human androgen receptor.’ Andrologia. Dec;37(6):211-2.
Page Owner: ma0041
Page Created: Wednesday 7 December 2016 14:17:24 by kj0008
Last Modified: Wednesday 22 February 2017 11:50:49 by kj0008
Expiry Date: Wednesday 7 March 2018 14:16:10
Assembly date: Tue Sep 19 11:47:17 BST 2017
Content ID: 168800